BOSTON, March 30, 2026 -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not...
Sean McCarthy to moderate panel, "Bridges Over Troubled Water and M&A "a la carte": Financing and Exiting", at Bio 2010 in Chicago, IL
News | 05. 05. 2010
